Navigation Links
Thomson Reuters Survey Finds Cancer Patients Forgoing Treatment Because of Cost
Date:10/13/2008

25 Percent of Late-Stage Patients Earning Under $40,000 Annually Say They

Have Chosen Not to Undergo Recommended Care

ANN ARBOR, Mich., Oct. 13 /PRNewswire/ -- The Healthcare business of Thomson Reuters today announced the publication of a new research report which analyzes the impact of cost on the cancer treatment decisions of individuals.

Entitled "The Cost of Cancer," the report aggregates survey responses from 1,767 adults currently being treated for cancer. It finds a clear link between patients' annual income and their decisions to curb cancer treatments due to cost -- even among patients with late-stage cancers.

The report notes that among the 569 survey respondents with late-stage cancer, 12.3 percent said they have passed up recommended treatment because it was too expensive. This figure varies dramatically by patient income level. Twenty-five percent of late-stage cancer patients who earn less than $40,000 a year said they have chosen not to undergo a recommended treatment due to cost -- compared with 11.2 percent of those earning between $40,000 and $80,000 per year and 4.8 percent of those earning more than $80,000 annually.

Similarly, 65 percent of all respondents with late-stage cancer said the out-of-pocket cost of treating their cancer has caused them distress. Among all cancer patients earning under $40,000 per year, that number jumps to 77 percent.

"The physical and emotional burden of illness is not the only challenge cancer patients face," said Bill Marder, PhD, senior vice president and general manager for the Healthcare business of Thomson Reuters. "Many also struggle to cope with medical costs. This survey shows that the cost of cancer treatment is affecting patients' ability to get the care they need."

Data for the report were aggregated using the Thomson Reuters NexProfiler(TM) Treatment Option Tool to identify and survey patients who are actively being treated for breast cancer, prostate cancer, colon cancer or lung cancer. The results are based on the responses of 1,767 adults who completed an online survey in May 2008 (39,882 were invited to participate via e-mail). All results have undergone statistical testing, and all comparisons are significant at the 95-percent confidence level, unless otherwise noted.

About Thomson Reuters

The Healthcare business of Thomson Reuters produces insights, information, benchmarks and analysis that enable organizations to manage costs, improve performance and enhance the quality of healthcare. Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq (Nasdaq: TRIN). For more information, go to http://www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Scientific Business of Thomson Reuters Predicts Nobel Laureates
2. Indonesias Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters
3. The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008
4. Three Aurora Hospitals Named Top Performers in National Thomson Reuters Annual Survey
5. Kansas Health Policy Authority Awards Thomson Reuters Contract for Health Care Data Integration and Analysis Initiative
6. Thomson Reuters Publishes CMR Internationals 2008 Pharmaceutical R&D Factbook, Now Available for the First Time Online
7. Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in Chinas Generics and API Market
8. CMS Selects Thomson Reuters to Help Detect Medicaid Fraud in Eight States
9. Thomson Reuters Adds Routes of Synthesis Data to Its Newport Horizon Premium and Newport Vision Premium Solutions
10. The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline
11. Thomson Reuters Honors Temple University Health System for Initiative That Cut Costs $64 Million and Grew Clinical Service Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose ... – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose ... products, garnering increased attention from all stakeholders in the development of new chemical ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for Healthcare ... Hospital on April 5-7. The series is a multi-day, multi-workshop event designed to ... cover a broad range of topics, including coaching skills, the scientific method of ...
(Date:2/12/2016)... ... 12, 2016 , ... The Jones Agency, a family owned insurance company with ... a cooperative charity drive with the Tarrant Area Food Bank in the hopes of ... families in need, the Tarrant County Food Bank offers hope and security to the ...
(Date:2/12/2016)... ... 2016 , ... Miami Dental Specialists is excited to bring patients the choice ... in January, Miami Dental Specialists will offer the non-metal implants as a safe, holistic ... be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology to ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, ... Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ways health ... therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016 On Thursday, Feb. 11, 2016, surgeons ... David,s North Austin Medical Center successfully completed the first ... ® Surgical System with Trumpf Medical,s advanced operating ... Lakshman , M.D., colorectal surgeon at the Texas Institute ... Table Motion technology, which seamlessly combines the da Vinci ...
(Date:2/12/2016)... , Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... announced the Company will ring the Nasdaq Closing Bell ... New York at 4:00 p.m. ET on ... Aralez. Adrian Adams , will perform ... 3:50 to 4:00 p.m. ET.  A live webcast will ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
Breaking Medicine Technology: